APX3330 ZETA-1 Clinical Data Presented at American Diabetes Association’s Annual Conference

Ocuphire Pharma, Inc. presented clinical data on their drug APX3330 in a late-breaker session at the American Diabetes Association's Annual Conference. The data showed that APX3330 reduced the worsening of diabetic retinopathy after 24 weeks of treatment. This could potentially shift the treatment paradigm for diabetic retinopathy and broaden the prescriber base to include primary care and endoc..